The Valley Desk

NCT04209855 · Interventional trial

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Overall registry status Completed

Phase 3

Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov